2-(2,3-dicarboxycyclopropyl) glycine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(2,3-dicarboxycyclopropyl) glycine
• 英文别名: 3-[Amino(carboxy)methyl]cyclopropane-1,2-dicarboxylic acid
• 化学式: C₇H₉NO₆
• 分子量: 203.152
• InChiKey: MATPZHBYOVDBLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  (2S,1'R,2'R,3'R)-N-t-butoxycarbonyl-2-(2,3-dimethoxycarbonylcyclopropyl)glycine methyl ester 在 盐酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 以65%的产率得到2-(2,3-dicarboxycyclopropyl) glycine
  参考文献：
  名称：

  2-(2,3-dicarboxycyclopropyl) glycine and method for producing the same

  摘要：

  提供了(2S,1'R,2'R,3'R)-2-(2,3-二羧基环丙基)甘氨酸(DCG-I)和(2S,1'S,2'S,3'S)-2-(2,3-二羧基环丙基)甘氨酸(DCG-II)的合成方法。使用DCG-I和DCG-II作为NMDA受体的激动剂研究L-谷氨酸受体，有助于开发治疗各种神经疾病的药物。此外，DCG-I和DCG-II即使在低浓度下也能选择性地抑制单突触反射，使它们成为治疗痉挛性麻痹、麻醉和镇痛的有用药物。

  公开号：

  US05334757A1

文献信息

• PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF
  申请人：Trauner Dirk

  公开号：US20090181454A1

  公开（公告）日：2009-07-16

  The present invention provides a synthetic regulator of glutamate receptor function, which regulator is a light-sensitive (photoreactive) regulator. The present invention further provides a light-regulated glutamate receptor that includes a subject synthetic regulator non-covalently associated with the glutamate receptor. Also provided are cells and membranes comprising a subject light-regulated glutamate receptor. The present invention further provides methods of modulating glutamate receptor function, involving use of light. The present invention further provides methods of identifying agents that modulate glutamate receptor function.

  本发明提供了一种合成的谷氨酸受体功能调节剂，该调节剂是一种光敏感（光反应性）调节剂。本发明还提供了一种光调节的谷氨酸受体，其中包括与谷氨酸受体非共价结合的主体合成调节剂。还提供了包括主体光调节谷氨酸受体的细胞和膜。本发明还提供了使用光调节谷氨酸受体的调节谷氨酸受体功能的方法。本发明还提供了识别调节谷氨酸受体功能的药剂的方法。
• New use of glutamate antagonists for the treatment of cancer
  申请人：Ikonomidou, Hrissanthi

  公开号：EP1002535A1

  公开（公告）日：2000-05-24

  New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compositions. They can be identified by appropriate screens.

  根据谷氨酸在癌症发病机制中的作用，可以设计出新的疗法。谷氨酸与 AMPA、kainate 或 NMDA 受体复合物相互作用的抑制剂可能有助于治疗癌症，并可配制成药物组合物。它们可以通过适当的筛选来确定。
• Neurogenesis by modulating angiotensin
  申请人：Braincells, Inc.

  公开号：EP2382975A2

  公开（公告）日：2011-11-02

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells.

  本发明描述了通过刺激或增加神经发生来治疗中枢和外周神经系统疾病和病症的方法。本发明包括基于调节血管紧张素活性以刺激或激活新神经细胞形成的组合物和方法。
• Compositions and methods for uncoupling TrkB receptor from PLC gamma 1 for the treatment of epilepsy and anxiety-like disorder
  申请人：DUKE UNIVERSITY

  公开号：US10369189B2

  公开（公告）日：2019-08-06

  The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides that when administered disrupt the physical interaction of TrkB with its signaling effector, phospholipase Cγ1 (PLCγ1). The invention further provides method of treatment comprising administering phosphopeptides that uncouple TrkB from PLCγ1 in order to prevent and/or ameliorate nervous system disorders such as epilepsy, anxiety, and seizures.

  本发明提供了用于预防或改善神经系统疾病的药物组合物及其使用方法。更具体地说，本发明提供了药物组合物，包括磷肽，当给药时，磷肽能破坏 TrkB 与其信号效应物磷脂酶 Cγ1 (PLCγ1)的物理相互作用。本发明进一步提供了治疗方法，包括施用能使TrkB与PLCγ1脱钩的磷酸肽，以预防和/或改善神经系统疾病，如癫痫、焦虑和癫痫发作。
• Ganaxolone for use in treatment of status epilepticus
  申请人：Marinus Pharmaceuticals, Inc.

  公开号：US11110100B2

  公开（公告）日：2021-09-07

  This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE.

  本发明涉及治疗癫痫状态的方法，其方法是向有需要的受试者静脉注射甘露醇酮和持续静脉注射神经类固醇。该方法可抑制癫痫状态并持续抑制癫痫状态。